ASX:ACW

Stock Analysis Report

Executive Summary

Actinogen Medical Limited, a biotechnology company, develops treatments for Alzheimer’s disease, and the cognitive deficiency associated with other neurological and metabolic diseases in Australia.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Actinogen Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ACW's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

46.7%

ACW

4.4%

AU Biotechs

7.1%

AU Market


1 Year Return

-59.3%

ACW

46.0%

AU Biotechs

-19.4%

AU Market

Return vs Industry: ACW underperformed the Australian Biotechs industry which returned 55.2% over the past year.

Return vs Market: ACW underperformed the Australian Market which returned -18.8% over the past year.


Shareholder returns

ACWIndustryMarket
7 Day46.7%4.4%7.1%
30 Day-12.0%-4.8%-21.3%
90 Day-42.1%5.8%-24.8%
1 Year-59.3%-59.3%47.5%46.0%-15.8%-19.4%
3 Year-66.2%-66.2%135.4%127.4%-2.4%-15.8%
5 Year-73.2%-73.2%220.2%199.9%8.4%-16.0%

Price Volatility Vs. Market

How volatile is Actinogen Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Actinogen Medical undervalued compared to its fair value and its price relative to the market?

2.04x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ACW's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ACW's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ACW is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ACW is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ACW's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ACW is good value based on its PB Ratio (1.9x) compared to the AU Biotechs industry average (2.4x).


Next Steps

Future Growth

How is Actinogen Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-46.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACW is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACW is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACW is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACW's revenue is expected to decline over the next 3 years (-39.9% per year).

High Growth Revenue: ACW's revenue is forecast to decline over the next 3 years (-39.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ACW's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Actinogen Medical performed over the past 5 years?

-20.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ACW is currently unprofitable.

Growing Profit Margin: ACW is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ACW is unprofitable, and losses have increased over the past 5 years at a rate of -20.7% per year.

Accelerating Growth: Unable to compare ACW's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.5%).


Return on Equity

High ROE: ACW has a negative Return on Equity (-56.27%), as it is currently unprofitable.


Next Steps

Financial Health

How is Actinogen Medical's financial position?


Financial Position Analysis

Short Term Liabilities: ACW's short term assets (A$9.2M) exceed its short term liabilities (A$809.3K).

Long Term Liabilities: ACW's short term assets (A$9.2M) exceed its long term liabilities (A$329.9K).


Debt to Equity History and Analysis

Debt Level: ACW is debt free.

Reducing Debt: ACW has not had any debt for past 5 years.


Balance Sheet

Inventory Level: ACW has a low level of unsold assets or inventory.

Debt Coverage by Assets: ACW's debt is not covered by short term assets (assets are -1.6650092449885E+17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACW has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ACW has less than a year of cash runway if free cash flow continues to reduce at historical rates of -32.9% each year


Next Steps

Dividend

What is Actinogen Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ACW's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACW's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACW's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACW's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average board tenure


CEO

Bill Ketelbey

5.33s

Tenure

AU$457,690

Compensation

Dr. John William Ketelbey, also known as Bill, MBBCH, FFPM, MBA, GAICD, has been the Chief Executive Officer and Managing Director at Actinogen Medical Limited since December 18, 2014. Dr. Ketelbey is res ...


CEO Compensation Analysis

Compensation vs Market: Bill's total compensation ($USD281.92K) is about average for companies of similar size in the Australian market ($USD245.57K).

Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
John Ketelbey
MD, CEO & Director5.33yrsAU$457.69k0.085% A$19.1k
George Morstyn
Non-Executive Director2.33yrsAU$71.66k0.018% A$4.0k
Geoffrey Edward Brooke
Non-Executive Chairman3.08yrsAU$160.02k0.12% A$26.5k
Colin Masters
Member of Xanamem Clinical Advisory Board5.08yrsno datano data
Jeffrey Cummings
Member of Xanamem Clinical Advisory Board5.08yrsno datano data
Malcolm McComas
Non-Executive Director1yrAU$18.53k0.045% A$10.0k
Craig Ritchie
Chairman of Xanamem Clinical Advisory Board5.08yrsno datano data

5.1yrs

Average Tenure

69yo

Average Age

Experienced Board: ACW's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.8%.


Top Shareholders

Company Information

Actinogen Medical Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Actinogen Medical Limited
  • Ticker: ACW
  • Exchange: ASX
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$22.325m
  • Shares outstanding: 1.12b
  • Website: https://www.actinogen.com.au

Location

  • Actinogen Medical Limited
  • 109 Pitt Street
  • Suite 901
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ACWASX (Australian Securities Exchange)YesOrdinary SharesAUAUDOct 2007
3ACDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2007
ACWCHIA (Chi-X Australia)YesOrdinary SharesAUAUDOct 2007
ATGG.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2007

Biography

Actinogen Medical Limited, a biotechnology company, develops treatments for Alzheimer’s disease, and the cognitive deficiency associated with other neurological and metabolic diseases in Australia. It is developing Xanamem, a therapy for Alzheimer’s disease; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild dementia due to Alzheimer’s disease. The company is also developing XanaHES, a Phase I, single blinded, central reader blinded, placebo-controlled, dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited is based in Sydney, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/01 10:36
End of Day Share Price2020/04/01 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.